Research programme: anticancer antibody therapeutics - AGY Therapeutics
Latest Information Update: 10 Oct 2006
Price :
$50 *
At a glance
- Originator AGY Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioblastoma; Solid tumours
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Glioblastoma in USA (unspecified route)
- 10 Oct 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 24 Jun 2004 Preclinical trials in Glioblastoma in USA (unspecified route)